Navigation Links
Monogram Announces 2008 Third Quarter Financial Results
Date:10/27/2008

es 83,323 70,551

Stockholders' deficit:

Common stock 135 134

Additional paid-in capital 290,634 286,196

Accumulated other comprehensive loss - (31)

Accumulated deficit (299,714) (287,539)

Total stockholders' deficit (8,945) (1,240)

Total liabilities and

stockholders' deficit $74,378 $69,311

(1) The consolidated balance sheet data at December 31, 2007 is derived from audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission.

Reconciliation of Revenue and Gross Margin on GAAP to Non-GAAP Basis

Total revenue and product gross margin is shown below in accordance with GAAP and also on a Non-GAAP basis to include deferred revenue related to the sale of the Company's assays in the Company's collaboration with Pfizer of $1.6 million and $0.4 million for the three months ended September 30, 2008 and 2007, respectively, and $3.6 million and $0.8 million for the nine months ended September 30, 2008 and 2007, respectively. The Company is reporting total revenue and product gross margin, on a Non-GAAP basis to provide a matching of revenue and expenses for product sales.

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Revenue ($ millions)

GAAP Product Revenue $15.5 $8.7 $45.0 $26.8

Add: Deferred Revenue from

sales of Trofile assays to Pfizer $1.6 $0.4 $3.6 $0.8

Non-GAAP Produ
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
2. Monogram Biosciences to Present at the ThinkEquity Partners Fifth Annual Growth Conference
3. Monogram Biosciences to Present at the JMP Securities Healthcare Conference
4. Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call
5. Monogram Announces Third Quarter 2007 Financial Results
6. Monogram Biosciences to Present at the Piper Jaffray 19th Annual Healthcare Conference
7. Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call
8. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
9. Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts
10. Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology
11. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... & Brussels (PRWEB) December 22, 2014 ... (CfPIE), the global leader of technical training across the ... for Clinical Data Management (SCDM) to provide the ... certification programs —providing access to the more than ... extends SCDM members with 10% off when registering for ...
(Date:12/22/2014)... 2014  Alternative Energy & Environmental Solutions, Inc., ... a letter of intent to acquire BioTechPharma Corporation, ... a nanotechnology-based development platform used to create drug ... on-site collection and testing to identify infectious disease, ... an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... 2014 The American Journal ... original research, reviews and editorials addressing developments and ... today published a provocative article exploring the role ... and potential treatment of prostate cancer. , ... proposes the possibility that there could be a ...
(Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
Breaking Biology Technology:CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... Stockholders Meeting to Approve Merger With Integra on October 11, ... ... IRVINE, California, September 5 IsoTis, Inc.,(NASDAQ: ISOT ) ... statement with the U.S. Securities and,Exchange Commission ("SEC") in connection with ...
... Pressure,BioSciences, Inc. (Nasdaq: PBIO ) today ... the Barocycler NEP2320, a patent-pending, lightweight,compressed air driven ... that it has been issued a CB Scheme ... has been found in,compliance with the IEC 61010-1 ...
... Sept. 5 Thermo Fisher,Scientific Inc. (NYSE: ... has,acquired the instrument sales business of Davis Inotek ... Instruments and excludes its,related calibration services. Davis Instruments ... control instruments, serving customers in a,wide range of ...
Cached Biology Technology:IsoTis Files Definitive Proxy Statement 2IsoTis Files Definitive Proxy Statement 3IsoTis Files Definitive Proxy Statement 4Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 2Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 3Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 4Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 2Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 3Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek 4
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans ... of Medicine. Funding for this $50 million capital project ... be publicly launched next summer. The ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to ... immediately with plans to be ready to welcome medical ...
(Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... CLEVELAND/ORLANDO University Hospitals Case Medical Center researchers could ... second chancejust not as they originally thought. LateTIME ... from bone marrow that were believed to have the ... injected into the heart within two weeks of the ...
... suffering from heart failure due to a previous myocardial ... year following an investigative treatment that involved infusing them ... 4 percent improvement average the researchers projected for the ... published today (Nov. 14) in The Lancet ...
... to understanding what drives tumor metastasis, as laboratory models ... their own growth. In a recent issue of ... Association for Cancer Research, Ral A. Ruggiero, Ph.D., a ... the National Academy of Medicine in Buenos Aires, Argentina, ...
Cached Biology News:Post heart attack recovery may not be aided by stem cell injections, but trial demonstrates promise 2Results triple researchers' projections with use of adult stem cells for heart failure 2
Permeabilization Solution, 5X...
Perm/Wash Buffer 250 Tests...
Complete PCR kit. Includes: MasterAmp™ Taq DNA Polymerase, 10X PCR Buffer, MasterAmp™ 10X PCR Enhancer, dNTP Mix, 2.5 mM each, 25 mM MgCl2, Enzyme Dilution Buffer, Control Template and Prim...
Rabbit polyclonal to 3-Ethynylestradiol ( Abpromise for all tested applications). Antigen: Ethynylestradiol conjugated to BSA....
Biology Products: